Department of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Albert-Ludwigs-University Freiburg, Freiburg, Germany.
Faculty of Biology, Albert-Ludwigs-University, Freiburg, Germany.
Cancer Res. 2019 Jan 1;79(1):183-195. doi: 10.1158/0008-5472.CAN-18-1397. Epub 2018 Nov 13.
MicroRNAs (miR) are small noncoding RNAs that regulate gene expression, posttranscription, and manipulate immune responses in different types of cancers. In this study, we identify miR-146a as a negative regulator of immune activation, comparable to immune-checkpoint molecules. miR-146a levels were increased in melanoma microenvironmental tissue, and mice survived longer and developed less metastases in comparison with wild-type melanoma-bearing mice. T cells isolated from mice revealed higher expression levels of the miR-146a target gene Stat1 and the Stat1-regulated cytokine IFNγ. Neutralization of IFNγ in mice decreased survival and increased melanoma metastasis patterns to those of wild-type mice. , IFNγ reduced melanoma cell migration, cell-cycle activity, and basal metabolic rate. Conversely, IFNγ also increased PD-L1 levels on the melanoma cells, which may counterbalance some of the beneficial effects increasing immune escape . Combined treatment with a miR-146a antagomiR and anti-PD-1 resulted in improved survival over isotype control or anti-PD-1 treatment alone. In summary, these data show that miR-146a plays a central role within the STAT1/IFNγ axis in the melanoma microenvironment, affecting melanoma migration, proliferation, and mitochondrial fitness as well as PD-L1 levels. Additionally, combined inhibition of PD-1 and miR-146a could be a novel strategy to enhance antitumor immune response elicited by checkpoint therapy. SIGNIFICANCE: These findings identify a microRNA-based mechanism by which melanoma cells escape the immune system, providing a new therapeutic strategy to improve the current management of patients with melanoma.
微小 RNA(miR)是一种小的非编码 RNA,可调节基因表达、转录后调控和操纵不同类型癌症的免疫反应。在这项研究中,我们发现 miR-146a 是一种免疫激活的负调节剂,可与免疫检查点分子相媲美。黑色素瘤微环境组织中的 miR-146a 水平升高,与野生型黑色素瘤荷瘤小鼠相比, 小鼠的存活率更高,转移瘤更少。与野生型小鼠相比,从 小鼠分离的 T 细胞显示出更高水平的 miR-146a 靶基因 Stat1 和 Stat1 调节的细胞因子 IFNγ。在 小鼠中中和 IFNγ 会降低存活率并增加黑色素瘤转移模式,使其类似于野生型小鼠。此外,IFNγ 降低了黑色素瘤细胞的迁移、细胞周期活性和基础代谢率。相反,IFNγ 还增加了黑色素瘤细胞上的 PD-L1 水平,这可能会抵消一些增加免疫逃逸的有益效果。联合使用 miR-146a 拮抗剂和抗 PD-1 治疗可改善存活率,优于单独使用同种型对照或抗 PD-1 治疗。总之,这些数据表明,miR-146a 在黑色素瘤微环境中的 STAT1/IFNγ 轴中发挥核心作用,影响黑色素瘤的迁移、增殖和线粒体适应性以及 PD-L1 水平。此外,联合抑制 PD-1 和 miR-146a 可能是增强检查点治疗引发的抗肿瘤免疫反应的新策略。意义:这些发现确定了一种基于微 RNA 的机制,通过该机制黑色素瘤细胞逃避免疫系统,为改善当前黑色素瘤患者的治疗提供了新的治疗策略。